Related Experiment Video

Updated: Mar 16, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

[Immune checkpoint antibodies increase survival in patients with metastatic melanoma]

Louise Elkjær Fløe1, Inge Marie Svane, Lars Bastholt

  • 1louiseev@me.com.

Ugeskrift for Laeger
|August 24, 2016
PubMed

Insights

Rising melanoma incidence and poor prognosis are improving with new immunotherapies. Treatments targeting cytotoxic T-lymphocyte-antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) pathways activate T-cells to fight cancer.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Melanoma incidence is increasing globally.
  • Metastatic melanoma historically has a poor survival prognosis.
  • Recent advancements focus on immune system modulation for cancer treatment.

Purpose of the Study:

  • To investigate the efficacy of novel immunotherapies targeting specific immune checkpoints in melanoma.
  • To explore the mechanisms by which anti-CTLA-4 and anti-PD-1 antibodies enhance anti-cancer immunity.

Main Methods:

  • Treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody.
  • Treatment with anti-programmed cell death (PD)-1 antibody.
  • Monitoring T-cell activation and anti-tumor response.

Main Results:

  • Both anti-CTLA-4 and anti-PD-1 antibodies demonstrate significant therapeutic potential.
  • These therapies work by blocking inhibitory receptors, thereby maintaining T-cell activation.
  • Activated T-cells are enabled to effectively attack cancer cells, improving outcomes.

Conclusions:

  • Targeting CTLA-4 and PD-1 represents a promising strategy for managing metastatic melanoma.
  • Immunotherapy offers a new paradigm in cancer treatment, improving survival prognosis.
  • Further research into immune checkpoint inhibitors is warranted for various cancers.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

14.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K